A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. (2nd September 2019)

• Record Type: Journal Article
• Authors: Park, Sunmin; Kim, Young; Yoon, Won Sup; Rim, Chai Hong
• Is Part Of: International journal of radiation biology. Volume 95:Number 9(2019)
• Page Start: 1287
• Page End: 1294
• Publication Date: 2019-09-02
• Subjects: Stereotactic body radiotherapy -- ultra-central tumor -- feasibility -- radiotherapy; Radiation -- Physiological effect -- Periodicals; Radiobiology -- Periodicals; 571.45
• DOI: 10.1080/09553002.2019.1626026
• Languages: English
• ISSNs: 0955-3002

Abstract

Abstract: Purpose: Administration of stereotactic body radiation therapy (SBRT) to ultra-central (UC) lung tumors, generally defined as those abutting the proximal bronchial trees, is difficult due to concerns about serious toxicities. Therefore, our institution has performed moderate-intensity SBRT. Patients and methods: Patients with UC tumors underwent SBRT at a dose of 50–60 Gy in 10 fractions, with D max in the target volume not exceeding 110% of the prescribed dose. The primary outcomes were tumor response and overall survival (OS). Results: From January 2017 to September 2018, we treated eight patients who had been diagnosed with UC tumors. The median follow-up time was 8.6 months (range: 2.7–14.9). Five of the eight patients (62.5%) showed a complete response (CR), two (25%) had a partial response (PR), and one (12.5%) had stable disease (SD); the response and disease control rates were 87.5% and 100%, respectively. Seven patients were alive with no evidence of disease or with controlled disease until the last follow-ups, except for one patient who died due to a non-RT cause at 3 months after SBRT. One patient experienced grade 2 esophageal pain and another had grade 1 cough. No grade 3 or higher toxicities were reported. Conclusion: Moderate-intensity SBRT might aid in achieving good control of UC tumors without excessive toxicities. Future studies involving larger numbers of patients and longer follow-up times are warranted to confirm the efficacy and feasibility.